Tolulope Akinade

Tolulope Akinade

Auto-generated profile, based on publicly available information

Tolulope Akinade

Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Biomaterials
Verified
Journal Article
Closed access
INIbtehaj Naqvi
Ibtehaj Naqvi
NGNicholas Giroux
Nicholas Giroux
LOLyra Olson
Lyra Olson
SMSarah Ahn Morrison
Sarah Ahn Morrison
TLTelmo Llanga
Telmo Llanga
BSBruce A. Sullenger
Bruce A. Sullenger

21 July 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
SCShuting S. Cai
Shuting S. Cai
TLTianyu Li
Tianyu Li
TATolulope Akinade
Tolulope Akinade
YZYuefei Zhu
Yuefei Zhu
KLKam W Leong
Kam W Leong

1 September 2020 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
HHHanyao Huang
Hanyao Huang
YHYapei Han
Yapei Han
TATolu Akinade
Tolu Akinade
JLJingtao Li
Jingtao Li
BSBing Shi
Bing Shi
CLChenghao Li
Chenghao Li

20 December 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DBDivya Bhansali
Divya Bhansali
TATolulope Akinade
Tolulope Akinade
TLTianyu Li
Tianyu Li
YZYiling Zhong
Yiling Zhong
FLFeng Liu
Feng Liu
KLKam W Leong
Kam W Leong
Conventionally, nanocarriers are used to regulate the controlled release of therapeutic payloads. Increasingly, they can also be designed to have an intrinsic therapeutic effect. For example, a positively charged nanocarrier can bind damage-associated molecular patterns, inhibiting toll-like receptor (TLR) pathway activation and thus modulating inflammation. These nucleic acid-binding nanomaterials (NABNs), which scavenge pro-inflammatory stimuli, exist in diverse forms, ranging from soluble polymers to nanoparticles and 2D nanosheets. Unlike conventional drugs that primarily address inflammation symptoms, these NABPs target the upstream inflammation initiation pathway by removing the agonists responsible for inflammation. Many NABNs have demonstrated effectiveness in murine models of inflammatory diseases. However, these scavengers have not been systematically studied and compared within a single setting. Herein, we screen a subset of the most potent NABNs to define their relative efficiency in scavenging cell-free nucleic acids and inhibiting various TLR pathways. This study helps interpret existing in vivo results and provides insights into the future design of anti-inflammatory nanocarriers.